Microbe: Are We Ready for the Next Plague?

Alan Zelicoff and Michael Bellomo

Amacom, New York, NY, 2005
ISBN: 0-8144-0865-6
Pages: 256; Price: US $23.00

Microbe: Are We Ready for the Next Plague? by Alan Zelicoff and Michael Bellomo is a comprehensive, yet succinct, account of the threat to public health posed by microbial pathogens. What distinguishes this book from the surfeit of recent books hyping the threat of bioterrorism are its balanced perspective and elucidation of naturally emerging disease threats, such as severe acute respiratory syndrome (SARS) or West Nile virus, as exotic entities requiring a rapid and effective response; Mother Nature is quite the bioterrorist herself. Early recognition that an event has occurred is key to containment of the nascent epidemic.

The authors provide sufficient basic science background to bring the uninitiated up to speed on a variety of exotic and recently introduced microbes in engagingly titled chapters such as “The Birds that Fell from the Sky” (West Nile), “Corona of Death” (SARS), and “Something in the Water” (Cryptosporidium). In addition, they describe hantavirus pulmonary syndrome, mad cow disease, and Legionnaires’ disease in the context of recent public health emergencies. The authors also explain why both smallpox and anthrax are more than abstract concerns as agents of bioterrorism, on the basis of weaponization history, intrinsic attributes, and realistic scenarios. An account of the 1970 smallpox outbreak, which occurred in Aralsk, Kazakhstan, as a consequence of open air testing of a smallpox weapon by the Soviets is an eye-opener; there should be no doubts about capability and intent after reading this story.

The scenarios are well chosen and informative; they highlight the importance of early recognition that “something has happened” and breaking the disease cycle close to the index case. The unifying theme of the book is the importance of syndrome-based surveillance in achieving this goal. The authors dismiss BIOWATCH (air-monitoring devices to detect and identify microbes in aerosol clouds) as a well-intended but expensive “work in progress,” to put it charitably. BIOSENSE is a national surveillance system that they say has not been implemented in any substantive way. I reluctantly find myself in agreement with these assessments and receptive to their suggestions to implement an emerging diseases reporting system based on syndromic reporting.

Healthcare providers recognize syndromes, not microbial diseases. How long did it take to recognize monkeypox in 2003? The hantavirus associated with lethal pulmonary syndrome in New Mexico in 1993 was recognized only when the pattern emerged among previously healthy young adults living in rustic conditions on a Navajo reservation. The authors describe a product they dub Syndromic Reporting Information System (SYRIS) as a “beta test” product that has been deployed on a limited, regional basis and promises to provide a near instantaneous map of syndromic reports and to comply with all Centers for Disease Control and Prevention requirements for electronic reporting systems. Like most good ideas, simplicity is central to the SYRIS concept; it is likely to succeed because participating doctors, nurses, and veterinarians (most of the exotic pathogens are zoonoses) can report syndromic occurrences in 15 seconds or less and will be rewarded with instantaneous feedback and tailored reports and alarms. While this section does read a bit like an infomercial, the concept is sound and worthy of serious consideration by public health officials and policy makers. This book is the best of its genre and is recommended for anyone interested in understanding and managing the risks associated with emerging microbial threats.

Peter B. Jahrling*

*National Institutes of Health, Bethesda, Maryland, USA

The AIDS Pandemic: Impact on Science and Society

Kenneth H. Mayer and H.F. Pizer, editors

Elsevier Academic Press, Amsterdam, the Netherlands, and Boston, Massachusetts, 2005
ISBN: 0-12-465271-9
Pages: 537; Price: US $84.95

As we enter the third decade of the AIDS pandemic, numerous texts explore the many aspects of AIDS and its consequences. Mayer and Pizer’s premise is that AIDS has transformed many of the disciplines that it has touched. For the most part, this well-written volume supports their thesis. The authors, all established researchers, tackle many of the major issues, including virology, immunology, vaccines, microbicides, and sexually transmitted diseases, as well as...
the global impact of HIV/AIDS. Each chapter provides a well-referenced overview of its topic with many references as recent as 2003.

One of the real strengths of this book is a chapter on quantitative science that explores not only the history of HIV clinical trials, but also the design and importance of clinical trials in general. This chapter should be required reading for those considering clinical research in HIV. The chapters on Africa and Asia ably contrast the differences in these areas of highest prevalence. Another strength is the discussion of HIV in correctional facilities and the challenge of caring for this population, including their coexisting conditions and illicit drug use. Lastly, the discussion of the economics of AIDS is especially welcome in this era of efforts to increase access to drugs worldwide.

Overall, this book fills a valuable niche. A relatively concise text, it reviews many aspects of HIV with a focus on how each topic has evolved over the years. A few tables are small, but overall the diagrams and charts are clear and legible. This book would be of interest to infectious disease fellows, HIV caregivers, and those involved in public health and health policy. I heartily recommend this book and plan to keep it handy for future reference.

Jeffrey L. Stephens*
*Mercer University School of Medicine, Macon, Georgia, USA

Address for correspondence: Jeffrey L. Stephens, Department of Internal Medicine, Mercer University School of Medicine, 707 Pine St, Macon, GA 31201, USA; fax: 478-301-5856; email: stephens_j@mercer.edu

**Tick-Borne Diseases of Humans**

Jesse L. Goodman, David T. Dennis, and Daniel E. Sonenshine, editors

ASM Press, Washington, DC, 2005
ISBN: 1-55581-23-4
Pages: 440, Price: US $119.95

During the past 2 decades, the scientific landscape of tickborne diseases has changed remarkably. In part because of advances in molecular biology, more than 10 new rickettsial diseases, several ehrlichial diseases, and novel agents of *Borrelia* and *Babesia* genera have been recognized. This renaissance of interest in tickborne infections benefits from advances in molecular phylogenetics and diagnostics, immunology, and informatics that provide tantalizing insights into the complexities of vectorborne infection. Tick-Borne Diseases of Humans is a well-referenced textbook that encompasses these new insights in vector biology and reviews the emerging epidemiology and clinical science of these diseases as they occur across the globe. The editors’ goal of providing a “comprehensive” resource is admirably fulfilled.

The book, consisting of 20 chapters by 40 contributors, is divided into 3 sections. The first section includes excellent reviews of tick biology and systematics, tick-pathogen interactions, host responses, and vector management. This section provides a superb overview. While thorough and up-to-date, occasional redundancy occurs between chapters by different authors that could have been streamlined with additional editing. A concise and well-written chapter on the clinical approach to diagnosis and management of these diseases also seems misplaced; it would fit in better at the start of the next section.

Section 2 of the book includes summaries of major and lesser known tickborne infections. These chapters each provide detailed information on specific vectors and pathogens and on the epidemiology and clinical characteristics of the diseases they cause. While the description of the molecular biology and vector ecology of these infections is generally excellent, the clinical discussions often lack the nuance and detail of current infectious diseases texts. Nevertheless, each chapter provides current and well-referenced information on disease manifestations, diagnosis, and treatment. Several chapters, i.e., those on

**Correction: Vol 11, No. 8**

In “Laboratory Exposures to Brucellae and Implications for Bioterrorism” by Pablo Yagupsky and Ellen Jo Baron, an error occurred in the dosage for rifampin prophylaxis.

On page 1184, first column, first paragraph, the correct dosage of rifampin is 600 mg once daily.

The corrected text appears in the online article at http://www.cdc.gov/ncidod/EID/vol11no08/04-1197.htm

We regret any confusion this error may have caused.

**Correction: Vol 11, No. 10**

In “Methicillin-resistant *Staphylococcus aureus* Necrotizing Pneumonia,” by Monica Monaco et al., an error occurred on page 1647, in the first full sentence of the third column. The sentence should read “On day 3 of admission, antimicrobial drug therapy was changed to linezolid (600 mg 2 times a day).”

The corrected text appears in the online article at http://www.cdc.gov/ncidod/EID/vol11no10/05-0776.htm

We regret any confusion this error may have caused.